1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,232 | 0,256 | 18.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.01. | JW THERAP-B (02126): GRANT OF SHARE OPTIONS AND GRANT OF RESTRICTED SHARE UNITS | 1 | HKEx | ||
| 29.12.25 | JW THERAP-B (02126): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 22.12.25 | JW THERAP-B (02126): CONTINUING CONNECTED TRANSACTION IN RELATION TO EXTENSION OF TERM OF VECTOR SUPPLY AGREEMENT | - | HKEx | ||
| JW THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.12.25 | JW THERAP-B (02126): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 12.12.25 | JW THERAP-B (02126): (1) APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR; (2) APPOINTMENT OF CHAIRMAN OF THE BOARD; (3) RESIGNATION OF CHIEF ... | 1 | HKEx | ||
| 08.12.25 | JW THERAP-B (02126): VOLUNTARY ANNOUNCEMENT - RESEARCH AND DEVELOPMENT UPDATE - PRESENTATION OF JWCAR201 IIT STUDY DATA AT THE 67TH AMERICAN SOCIETY OF ... | - | HKEx | ||
| 28.11.25 | Imugene And JW Therapeutics Collaborate On Solid Tumor Therapy | - | RTTNews | ||
| 30.10.25 | JW THERAP-B (02126): MAJOR TRANSACTION IN RELATION TO AMENDMENT NO. 1 TO THE COLLABORATION AGREEMENT | - | HKEx | ||
| 21.10.25 | JW THERAP-B (02126): VOLUNTARY ANNOUNCEMENT - RESEARCH AND DEVELOPMENT UPDATE - DATA SUBMITTED FROM PHASE I STUDY OF RELMA-CEL IN CHINESE ADULT PATIENTS ... | 1 | HKEx | ||
| 10.10.25 | China Reviews JW Therapeutics' Plan to Use Own Lentiviral Vector to Cut Cost of CAR-T Cancer Drug | 1 | Yicai Global | ||
| 09.10.25 | JW THERAP-B (02126): VOLUNTARY ANNOUNCEMENT - RESEARCH AND DEVELOPMENT UPDATE - NATIONAL MEDICAL PRODUCTS ADMINISTRATION OFFICIALLY ACCEPTED THE POST-MARKETING ... | - | HKEx | ||
| 30.09.25 | JW THERAP-B (02126): DELAY IN DESPATCH OF CIRCULAR | - | HKEx | ||
| 25.09.25 | JW THERAP-B (02126): 2025 INTERIM REPORT | - | HKEx | ||
| 16.09.25 | JW THERAP-B (02126): GRANT OF SHARE OPTIONS | 2 | HKEx | ||
| 27.08.25 | JW THERAP-B (02126): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND CHANGE IN USE OF NET PROCEEDS FROM LISTING | - | HKEx |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 328,93 | 0,00 % | Praxis Precision Medicines Q4 2025 Earnings Preview | ||
| QIAGEN | 41,550 | +0,48 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 46 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Inmitten der Übernahmespekulationen liefere der... ► Artikel lesen | |
| VERA THERAPEUTICS | 44,070 | +2,85 % | Atacicept's Potential Approval Drives Favorable Views on Vera Therapeutics (VERA) | ||
| IMMUNOVANT | 26,650 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 22,410 | 0,00 % | Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating | ||
| SENSEI BIOTHERAPEUTICS | 26,010 | 0,00 % | Sensei Biotherapeutics Stock Soars 230% After Faeth Deal | ||
| AVIDITY BIOSCIENCES | 72,83 | -0,04 % | Avidity: Vielversprechende Studienergebnisse für Medikament gegen myotone Dystrophie | ||
| RECURSION PHARMACEUTICALS | 3,540 | 0,00 % | Aktien New York Ausblick: Gewinne erwartet - Nvidia führt Tech-Riesen an | NEW YORK (dpa-AFX) - Nach ihrem verhaltenen Auftakt in die verkürzte Börsenwoche dürften die US-Aktienmärkte am Mittwoch einen Erholungsversuch starten. Bevor am Abend das Sitzungsprotokoll der US-Notenbank... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 18,450 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day | The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by positive... ► Artikel lesen | |
| TANGO THERAPEUTICS | 12,410 | 0,00 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 29,200 | +0,48 % | Rapport Therapeutics, Inc.: Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline | U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,350 | 0,00 % | Cogent Biosciences, Inc. - 10-K, Annual Report | ||
| SUMMIT THERAPEUTICS | 15,880 | 0,00 % | Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough | ||
| STRUCTURE THERAPEUTICS | 68,26 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 30,150 | +0,23 % | Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 | - Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions -
- Presenting at the 44th Annual J.P. Morgan... ► Artikel lesen |
Das Unternehmen JW CAYMAN THERAPEUTICS CO LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,224 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JW CAYMAN THERAPEUTICS CO LTD finden Sie auf Wallstreet Online.